Can Sun’s Novel Partnered Topical Drug Alter Acne Options?
Sun-Cassiopea’s novel mechanism of action acne drug sees a “fair degree” of early physician interest in the US, with some analysts expecting the topical androgen receptor inhibitor to emerge as a key addition to the Indian’s firm’s specialty portfolio.
You may also be interested in...
Sun Pharma has expanded its dermatology portfolio by entering into a partnership with Italy’ Cassiopea to market Winlevi (clascoterone) 1% cream in the US and Canada, and expects to make it available in the US inthe fourth quarter of 2021.
India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.
Teva has launched the first US generic version of Absorica (isotretinoin), expanding its dermatological portfolio. The company has also launched generic erythromycin tablets in the US. Meanwhile, in its recent environmental, social and governance progress report, Teva has launched a plan to increase access to medicines globally by 2025.